HDAC6-IN-75
Based on 1 Customer Validation
HDAC6-IN-75 is a selective HDAC6 inhibitor with an IC50 of 0.17 nM against HDAC6. HDAC6-IN-75 induces the accumulation of acetylated α-tubulin in glioma cells. HDAC6-IN-75 triggers cell cycle changes, increases the SubG1 cell population, and promotes apoptosis in glioma cells and glioblastoma stem cells. HDAC6-IN-75 is applicable for glioma-related research.
For research use only. We do not sell to patients.
- Purity : 99.86%
- CAS No.: 400078-78-6
- Formula: C13H12N2O4S
- Molecular Weight:292.31
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
HDAC6 0.17 nM () |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Cancer cell lines | EC50 |
5 μM
Compound: 7a
|
Concentration of compound required for acetylation of histone-4 in human T24 cancer cells
Concentration of compound required for acetylation of histone-4 in human T24 cancer cells
|
[PMID: 11597413] |
In Vitro
HDAC6-IN-75 (compound 3a) (0.0032-50 μM; 24-72 h) exhibits time-dependent cytotoxicity in glioma cell lines, with GI50 values ranging from 0.8 μM to 5.3 μM after 72 h of incubation, and induces total growth inhibition in HOG, T98G, and U251MG cells at 72 h[1].
HDAC6-IN-75 (compound 3a) (34.0 μM HOG, 16.2 μM T98G, 50 μM U87MG, 28.9 μM U251MG; 24 h) increases acetyl-α-tubulin levels in all four tested glioma cell lines and acetyl-histone H3 levels in HOG, T98G, and U251MG cells after 24 h of treatment, consistent with its HDAC6 inhibitory activity and concurrent class I HDAC inhibition at cellular concentrations[1].
HDAC6-IN-75 (compound 3a) (34.0 μM HOG, 16.2 μM T98G, 50 μM U87MG, 28.9 μM U251MG; 24 h) induces DNA fragmentation (SubG1 accumulation) in T98G and U251MG cells, and modulates cell cycle progression by shifting populations from G0/G1 to G2/M in U87MG, U251MG, and HOG cells after 24 h of treatment[1].
HDAC6-IN-75 (compound 3a) (34.0 μM HOG, 16.2 μM T98G, 50 μM U87MG, 28.9 μM U251MG; 24 h) reduces viability and induces late apoptosis and necrosis in HOG and U251MG glioma cells after 24 h of treatment[1].
HDAC6-IN-75 (compound 3a) (0.0032-50 μM; 72 h) exhibits cytotoxicity against glioblastoma stem cells, with an IC50 of 3.725 μM in proneural GSC23 cells and 12.90 μM in mesenchymal GG16 cells after 72 h of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Glioma cell lines HOG, T98G, U87MG, U251MG
-
Concentration:34.0 μM (HOG); 16.2 μM (T98G); 50 μM (U87MG); 28.9 μM (U251MG)
-
Incubation Time:24 h
-
Result:Significantly promoted accumulation of acetyl-α-tubulin in HOG, T98G, U87MG, and U251MG cells.
Significantly promoted accumulation of acetyl-histone H3 in HOG, T98G, and U251MG cells, with activity comparable to vorinostat in these cell lines.
-
Cell Line:Glioma cell lines HOG, T98G, U87MG, U251MG
-
Concentration:34.0 μM (HOG); 16.2 μM (T98G); 50 μM (U87MG); 28.9 μM (U251MG)
-
Incubation Time:24 h
-
Result:Increased the percentage of cells in the SubG1 phase in T98G and U251MG cells.
Decreased the percentage of cells in the G0/G1 phase and increased the percentage in the G2/M phase in U87MG and U251MG cells.
Decreased the percentage of cells in the G0/G1 phase in HOG cells.
-
Cell Line:Glioma cell lines HOG, T98G, U87MG, U251MG
-
Concentration:34.0 μM (HOG); 16.2 μM (T98G); 50 μM (U87MG); 28.9 μM (U251MG)
-
Incubation Time:24 h
-
Result:Decreased cell viability in all four glioma cell lines.
Increased the percentage of late apoptotic and necrotic cells in HOG and U251MG cells.
Chemical Information
-
CAS No. 400078-78-6
-
Appearance Solid
-
Molecular Weight 292.31
-
Formula C13H12N2O4S
-
Color White to off-white
-
SMILES
O=C(NO)C1=CC=C(NS(=O)(C2=CC=CC=C2)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (342.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4210 mL | 17.1051 mL | 34.2103 mL | 85.5256 mL |
| 5 mM | 0.6842 mL | 3.4210 mL | 6.8421 mL | 17.1051 mL | |
| 10 mM | 0.3421 mL | 1.7105 mL | 3.4210 mL | 8.5526 mL | |
| 15 mM | 0.2281 mL | 1.1403 mL | 2.2807 mL | 5.7017 mL | |
| 20 mM | 0.1711 mL | 0.8553 mL | 1.7105 mL | 4.2763 mL | |
| 25 mM | 0.1368 mL | 0.6842 mL | 1.3684 mL | 3.4210 mL | |
| 30 mM | 0.1140 mL | 0.5702 mL | 1.1403 mL | 2.8509 mL | |
| 40 mM | 0.0855 mL | 0.4276 mL | 0.8553 mL | 2.1381 mL | |
| 50 mM | 0.0684 mL | 0.3421 mL | 0.6842 mL | 1.7105 mL | |
| 60 mM | 0.0570 mL | 0.2851 mL | 0.5702 mL | 1.4254 mL | |
| 80 mM | 0.0428 mL | 0.2138 mL | 0.4276 mL | 1.0691 mL | |
| 100 mM | 0.0342 mL | 0.1711 mL | 0.3421 mL | 0.8553 mL |